25
Mar

Cambridge, MA-based NeuroPhage Pharmaceuticals has banked a $17 million venture round designed to fuel their early-stage work on a full slate of neurodegenerative disease targets like Alzheimer’s and Parkinson’s disease.

…read more

Source: NeuroPhage adds a $17M round to back Alzheimer’s drug program

    

0 No comments